SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Jemal A,Murray T,Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005; 55: 1030.
  • 2
    Boige V,Taieb J,Hebbar M, et al. Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level. Eur J Cancer. 2006; 42: 456459.
  • 3
    Rougier P,Ducreux M,Kerr D, et al. A phase II study of raltitrexed (‘Tomudex’) in patients with hepatocellular carcinoma. Ann Oncol. 1997; 8: 500502.
  • 4
    Hebbar M,Ernst O,Cattan S, et al. Phase II trial of docetaxel therapy in patients with advanced hepatocellular carcinoma. Oncology. 2006; 70: 154158.
  • 5
    Ulrich-Pur H,Kornek GV,Fiebiger W,Schull B,Raderer M,Scheithauer W. Treatment of advanced hepatocellular carcinoma with biweekly high-dose gemcitabine. Oncology. 2001; 60: 313315.
  • 6
    Taieb J,Bonyhay L,Golli L, et al. Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using 2 different schedules. Cancer. 2003; 98: 26642670.
  • 7
    Louafi S,Boige V,Ducreux M, et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC). Results of a phase II study. Cancer. 2007; 109: 13841390.
  • 8
    Therasse P,Arbuck S,Eisenhauer E, et al. New guidelines to evaluate the response to treatment in solid tumours. Special article. J Natl Cancer Inst. 2000; 92: 205216.
  • 9
    Barbare JC,Bouche O,Bonnetain F, et al. Treatment of advanced hepatocellular carcinoma with long-acting octreotide: preliminary results of a randomized placebo-controlled trial (FFCD-ANGH 2001-01 CHOC) [abstract]. Proc Am Soc Clin Oncol. 2005; 23: 4036a.
  • 10
    Llovet J,Ricci S,Mazzaferro V, et al. Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC) [abstract]. Proc Am Soc Clin Oncol. 2007; 25: LBA1.
  • 11
    Philip PA,Mahoney MR,Allmer C, et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol. 2005; 23: 66576663.
  • 12
    Thomas MB,Dutta A,Brown T, et al. A phase II open-label study of OSI-774 (NSC 718781) in unresectable hepatocellular carcinoma [abstract]. Proc Am Soc Clin Oncol. 2005; 23: 4083a.
  • 13
    Zhu AX,Stuart K,Blaszkowsky LS, et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer. 2007; 110: 581589.
  • 14
    Gruenwald V,Wilkens L,Gebel T, et al. A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma: final results [abstract]. Proc Am Soc Clin Oncol. 2007; 25: 4598a.
  • 15
    Ramanathan RK,Belani CP,Singh DA, et al. Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor tyrosine kinase 1 and 2 (Her2/Neu) in patients with advanced biliary tree cancer or hepatocellular cancer. A California Consortium (CCC-P) trial [abstract]. Proc Am Soc Clin Oncol. 2006; 24: 4010a.
  • 16
    Schwartz JD,Schwartz M,Lehrer D, et al. Bevacizumab in unresectable hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein [abstract]. Proc Am Soc Clin Oncol. 2006; 24: 4144a.
  • 17
    Zhu AX,Blaszkowsky LS,Ryan DP, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. JClin Oncol. 2006; 24: 18981903.
  • 18
    Torimura T,Sata M,Ueno T, et al. Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum Pathol. 1998; 29: 986991.
  • 19
    Schiffer E,Housset C,Cacheux W, et al. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology. 2005; 41: 307314.
  • 20
    Ito Y,Takeda T,Sakon M, et al. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer. 2001; 84: 13771383.
  • 21
    Huether A,Hopfner M,Baradari V,Schuppan D,Scherubl H. EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochem Pharmacol. 2005; 70: 15681578.
  • 22
    Cunningham D,Humblet Y,Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004; 351: 337345.
  • 23
    Caussanel JP,Levi F,Brienza S, et al. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst. 1990; 82: 10461050.
  • 24
    Gamelin L,Boisdron-Celle M,Delva R, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res. 2004; 10: 40554061.
  • 25
    Fleming FR. One sample multiple testing procedure for phase II clinical trials. Biometrics. 1982; 38: 143151.
  • 26
    Hu Z,Evarts RP,Fujio K, et al. Expression of transforming growth factor alpha/epidermal growth factor receptor, hepatocyte growth factor/c-met and acidic fibroblast growth factor/fibroblast growth factor receptors during hepatocarcinogenesis. Carcinogenesis. 1996; 17: 931938.
  • 27
    Patt YZ,Hassan MM,Lozano RD, et al. Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. Cancer. 2005; 103: 749755.
  • 28
    Lin AY,Brophy N,Fisher GA, et al. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma. Cancer. 2005; 103: 119125.
  • 29
    Zhu AX,Sahani DV,di Tomaso E, et al. A phase II study of sunitinib in patients with advanced hepatocellular carcinoma [abstract]. Proc Am Soc Clin Oncol. 2007; 25: 4637a.
  • 30
    Faivre SJ,Raymond E,Douillard J, et al. Assessment of safety and drug-induced tumor necrosis with sunitinib in patients with unresectable hepatocellular carcinoma [abstract]. Proc Am Soc Clin Oncol. 2007; 25: 3546a.
  • 31
    Saltz L,Kies M,Abbruzzese JL,Azarnia N,Needle M. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies [abstract]. Proc Am Soc Clin Oncol. 2003; 22: 817a.
  • 32
    Perez-Soler R,Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol. 2005; 23: 52355246.
  • 33
    Tejpar S,Peeters M,Humblet Y, et al. Dose-escalation study using up to twice the standard dose of cetuximab in patients with metastatic colorectal cancer with no or slight skin reactions on cetuximab standard dose treatment (EVEREST study): preliminary data [abstract]. Proc Am Soc Clin Oncol. 2006; 24: 3554a.